Azithromycin for early worsening of idiopathic pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have an acute flare-up of idiopathic pulmonary fibrosis that is mild or early-to-moderate
- Have a score at or below 13 on the SCALE-IPF severity scale (as used in this study)
- Be able to receive study care through the Assiut University IPF research program (2022–2026)
- Not need a breathing machine or admission to an intensive respiratory care unit
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
This trial tests whether adding zinc and nicotinamide riboside (a vitamin B3-like supplement) to standard IPF treatment can help improve lung function. It is for people with IPF who are already seeing a lung doctor and live in certain states.
This trial tests a treatment to reduce certain antibodies in the blood that may be making your idiopathic pulmonary fibrosis (IPF) worse. The goal is to slow down the progression of the disease and help you breathe easier.
This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.